{"entity":{"id":"leah-labs","kind":"company","name":"LEAH Labs","aka":[],"tldr":"LEAH Labs makes CAR-T cell therapy for dogs with lymphoma, using virus-free gene editing to bring the cost of a dose down to hundreds of dollars.","summary":"LEAH Labs (LifEngine Animal Health Laboratories) is developing CAR-T cell therapy for dogs with B-cell lymphoma, the naturally occurring counterpart of human non-Hodgkin lymphoma, using a non-viral gene-editing approach that the company says brings manufacturing cost to roughly $500 per dose. Its YC profile reports remissions in dogs with late-stage lymphoma. Veterinary cell therapies are regulated by the USDA rather than the FDA, which the company uses to iterate faster; the stated long-term aim is to carry the platform into human oncology.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/leah-labs"},{"label":"Official website","url":"https://www.leahlabs.com"}],"tags":["veterinary","comparative-oncology"],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Minneapolis, MN","country":"US","companyType":"cell-therapy","website":"https://www.leahlabs.com","stage":"startup","ycBatch":"W19","investors":["y-combinator"],"funding":[]},"route":"/companies/leah-labs/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}